INTRODUCTION
Patients with systemic lupus erythematosus (SLE)' produce a wide variety of autoantibodies. The hallmark of this disease is the presence of antibodies to DNA, although many patients have antibodies specific for other nuclear and cytoplasmic antigens (1) . Until recently, the study of autoantibodies has been limited to those naturally occurring in patients' sera and therefore has been restricted to an analysis of polyclonal immunoglobulin molecules.
As a first step toward the study of potentially crossreactive idiotypes common to autoantibodies produced by patients with SLE, we have produced monoclonal autoantibodies by hybridizing B lymphocytes from a patient with this disease with cells from two human myeloma cell lines. Using one of these lines and B lymphocytes from a patient with subacute sclerosing panencephalitis, Croce et al. (2) succeeded in producing bridomas by using a different myeloma line (7) . Both of these myeloma lines are mutant lines; this allows for the selection of hybrids in selective medium. In addition to this method, we also produced hybridomas using a nonmutant myeloma line and a technique of hybrid selection with wide applicability.
Peripheral blood mononuclear cells from patients with SLE include a large number of spontaneous immunoglobulin-secreting cells (8) . The number of such cells is directly correlated with disease activity (9) . Others have also demonstrated that some of these cells secrete autoantibody (10) . Therefore, hybridomas produced by fusion of peripheral blood B lymphocytes from patients with active SLE may be expected to produce autoantibodies representative of the immunoglobulin products of these activated cells. In the present work we screened hybridomas for those secreting antibodies to DNA and to extractable nuclear antigen (ENA). These two autoantibodies have been shown to be among the most prevalent in the sera of patients with severe SLE and were present in the serum of the B lymphocyte donor (1) . METHODS SLE patient B lymphocytes. A patient with active SLE and high titers of anti-ENA and anti-DNA antibodies donated B lymphocytes for fusion. 500 ml of heparinized blood was obtained, the buffy coat was isolated, and the erythrocytes were reinfused. Mononuclear cells were then separated from the buffy coat by Ficoll-Hypaque (LSM, Litton Bionetics, Kensington, MD) density-gradient centrifugation (11) . These cells were then depleted of T lymphocytes by two cycles of rosette formation with sheep erythrocytes. Nonrosetted cells were depleted of monocytes by plastic adherence (12 In addition, l0' M hypoxanthine, 4 X 10-7 M aminopterine, and 1.6 X i0' M thymidine (HAT) were added to prevent growth of unf used myeloma cells. Immediately after fusion, >85% of the cells excluded trypan blue (viable), and many multinucleated cells were present. 30 cultures of 1 ml each were established in 12-mm diam wells in 24-well plates (Costar, Cambridge, MA). After 2 d incubation at 370C in humidified air containing 7% carbon dioxide, 1 ml of the same medium was added to each well. Thereafter, 1 ml of medium was removed and replaced with 1 ml of fresh medium three times per week. After cell growth was established (26 d), cultures were fed with supplemented medium without aminopterin. By this time, control cultures of unfused GM 1500-6TG-AL2 cells were dead (100% trypan blue positive). After 7 d more of culture, hypoxanthine and thymidine were also omitted from the culture medium. Cultures were expanded in 50-ml tissue culture flasks before cloning.
Fusion method: nonmutant myeloma cell line. 8226 myeloma line obtained from the American Type Culture Collection, Silver Spring, MD, was maintained in RPMI 1640 supplemented as above but without 6-thioguanine. As originally described by Wright (14) , diethylpyrocarbonate (DEPC, Sigma Chemical Co.) was used to render these cells incapable of growth unless they were successfully rescued by fusion. Tubes containing 8226 myeloma cells with varying dilutions of DEPC were incubated for 30 min in ice water to define the lowest concentration that could prevent cell division but maintain short-term viability. Cells were first suspended in sterile phosphate-buffered saline (PBS), pH 7.4, at 10 million per milliliter. DEPC was diluted in absolute ethanol to 10-fold the desired final treatment concentration.
'/A0 vol of DEPC was then added to 9'/I vol of cells and mixed.
This was performed in a fume hood using a 50-ml centrifuge tube. After treatment the tube was filled with RPMI 1640 containing 10% FCS. Cells were washed three times to remove unhydrolyzed DEPC. In preliminary experiments, cell counts and viability determinations were performed. Cells were cultured for 2 wk after DEPC exposure to ensure adequate treatment. The ability of treated cells to incorporate tritiated thymidine was determined by pulsing a 0.1-ml culture containing 50 thousand cells with 1 ,uCi of tritated thymidine for 4 h in quadruplicate microtiter plate wells. The results of these preliminary studies indicated that the optimal concentration of DEPC was 1 X i0' vol/vol. In practice, myeloma line 8226 was treated with this concentration of DEPC and with concentrations onehalf and twice this amount. Unfused treated cells were always incubated as a control for adequate treatment with DEPC. In the fusion described, DEPC treatment was at 2 X i0' vol/vol and unfused 8226 cells exposed to this DEPC concentration failed to grow.
Fusion of line 8226 with B lymphocytes was performed identically to the method described above for fusion with GM 1500-6TG-AL2, except HAT was not required. Culture conditions for these hybrid cells were also as described above. Screening procedures: enzyme-linked immunoassay (ELISA). Initial screening for hybridomas producing immunoglobulin and specific antibodies was performed using a solid-phase micro-ELISA and alkaline phosphatase-conjugated, affinitypurified, heavy chain-specific, goat anti-human immunoglobulin (Sigma Chemical Co.) (15) . IgA, IgG, and IgM concentrations were determined by incubating 150 Ml of 1:1,000 goat anti-human immunoglobulin (heavy chain class-specific, Sigma Chemical Co.) in bicarbonate buffer, pH 9.6, in each polystyrene plastic microtiter plate well (Immulon Plate, Dynatech Corp., Alexandria, VA) overnight. Wells were washed repetitively with PBS, pH 7.2, containing 0.5% Tween 20. 100 ul of supernate to be tested or of a known amount of human immunoglobulin was added to each well. Human immunoglobulin standards were diluted in tissue culture medium with the same concentration of FCS as the supernates. Plates were incubated for 2 h at room temperature and washed. 100 Ml of the appropriate alkaline phosphatase-conjugated reagent (diluted in 1% FCS containing PBS-Tween 20 buffer) was added to each well and the plates were incubated another 2 h at room temperature. After washing, 100 Ml of substrate, p-nitrophenol phosphate (Sigma Chemical Co.) diluted in diethanolamine buffer, pH 9.8, was added to each well and incubated for 45 min. The optical density at 405 nm was then determined for each well. After construction of a standard curve, the class-specific immunoglobulin concentration of each supernate was determined. This assay was sensitive to <1 ng/ml.
Antibodies to ENA were detected using a similar ELISA.
ENA, prepared according to the method of Sharpe et al. (16) was the kind gift of Dr. The ELISA assay for anti-DNA antibody was performed by using modifications of previously reported methods (17) (18) (19) . Calf thymus DNA (Sigma Chemical Co.) was first dissolved in 0.1 M Tris-buffered saline (TBS), pH 7.4. 100 Ml of poly-L-lysine (PLL) at 50 Mg/ml in distilled water (Sigma Chemical Co.) was added to each well of a flexible polyvinyl chloride microtiter plate (Dynatech Corp.). Plates were incubated for 1 Table I . Only one of 30 culture wells resulting from fusion of DEPC-treated 8226 cells exhibited growth, while all 30 wells from the GM 1500-6TG-AL2 fusion contained viable cells. Supernates of these cultures were screened for immunoglobulin 18 d after fusion. All 30 culture wells from the GM 1500-6TG-AL2 fusion were positive for IgG (also produced by the GM 1500-6TG-AL2 line), 10 Later, only one well from this fusion continued to exhibit stable growth and the supernate of this culture contained IgG. The 8226 myeloma line did not produce immunoglobulin heavy chains but did produce kappa light chains. In addition to screening for immunoglobulin production, supernates from all fusion culture wells were tested for anti-DNA activity. Both the ELISA assay and the DNA-binding nitrocellulose filter assay were used. Results are shown in Table II . 20 supernates were positive for ds-DNA binding in the nitrocellulose filter assay while 13 were positive in the ELISA assay. Some supernates positive in one assay were negative in the other. Patient sera were positive in both assays, indicating potential differences in the behavior of monoclonal anti-DNA antibodies as compared with that of polyclonal anti-DNA antibodies in these two assays. Differences were not explained by greater sensitivity of one assay since for each assay some supernates were positive in one assay and negative in the other (Table  III) . As discussed later, these results could possibly be explained by low affinity anti-DNA activity.
Anti-ENA activity was present in four supernates. The results of screening for anti-ENA antibodies are given in Table IV longer absorbed by 100 Mg of ds-DNA. The anti-ds-DNA activity of this antibody was confirmed by immunoprecipitation of tritiated ds-DNA and '4C-ds-DNA in PEG after incubation with clone No. 38 IgM. '4C ss-DNA was not precipitated by this antibody (see Fig. 2, top) . Lastly, as illustrated on the bottom of Fig. 2 , clone No. 38 IgM was found to react preferentially with the synthetic double-stranded polydeoxynucleotide poly(dC) * poly(dG). There was little reactivity with poly(dC-dG)* poly(dC-dG), poly-(dA). poly(dT), or poly(dA-dT). poly(dA-dT). For This method of selection has wide applicability. In the fusions reported here, however, many fewer hybridomas resulted from fusion with DEPC-treated myeloma line 8226 than from hybridization with the HGPRT-deficient line GM 1500-6TG-AL2. It is possible that use of less toxic concentrations of DEPC would result in better rescue efficiency. The ability to produce human hybridomas that secrete autoantibodies is an important step toward understanding the binding characteristics of these antibodies. It also allows for the sampling of the immunoglobulin product of individual B lymphocytes that are present in the blood of a patient with SLE (or another autoimmune disease) and that are activated for immunoglobulin secretion at that point in time. Lastly, it will facilitate the study of idiotypes on human autoantibodies, a study which may enhance our understanding of B lymphocyte abnormalities in autoimmune diseases such as SLE.
Characterization of the binding specificities of one monoclonal anti-DNA, clone No. 38 IgM, serves as an example. We found this antibody to be reactive with ds-DNA. Anti-DNA activity was absorbed by ds-DNA and not by ss-DNA. This antibody precipitated radiolabeled ds-DNA and not ss-DNA in the presence of PEG. This could be the result of either antibody spec- ificity for ds-DNA or preferential affinity for ds-DNA over ss-DNA determinants. However the affinity of binding was probably low since the immune complex could not be precipitated in a Farr assay using 50% saturated ammonium sulfate (data not shown). This observation has previously been shown to be due to the high salt concentration that dissociates low affinity anti-DNA-DNA complexes (21) .
Lastly, this antibody was found to be reactive with A number of studies over the past 20 yr have indicated the exquisite specificity possible for antibodies to DNA. Experimental immunization of animals has led to antibodies capable of distinguishing thymidylic acid from thymidine and other nucleotides (25, 26) . Also, sera of patients with SLE have been found to contain, in addition to antibodies to native and denatured DNA, antibodies specific for nucleotides, nucleosides, and bases (27) (28) (29) . Finally, both induced and naturally occurring antibodies are capable of distinguishing polymers (30) . Thus, antibodies reactive with poly(dA-dT) did not react with poly(dG)* poly(dC). Antibodies induced in rabbits to poly(rA).poly(rU) did not react with poly(rG) * poly(rC) (31) . More recent studies have emphasized that determinants specific for the DNA double helix structure may be recognized by specific antibodies (6, 32) . In view of these studies, it is not surprising that we found an antibody with specificity for poly(dG) * poly(dC).
Taken together, these observations may also explain why many monoclonal anti-DNA in this study behave differently in different assays. For example, the highly specific antigenic determinant on poly(dG) * poly(dC) ds-DNA recognized by clone No. 38 IgM must be present in only a few areas of native DNA polymers. Assays based on the ability of anti-DNA to cross-link DNA may not detect a monoclonal antibody with very restricted DNA reactivities. Such an antibody would bind to native DNA with low affinity.
As noted above, the monoclonal antibodies obtained by hybridizing B lymphocytes from a patient with SLE represent a sample of the potential immunoglobulin products from those B lymphocytes that were activated in vivo and destined to secrete immunoglobulin. In the present work, the large number of immunoglobulin and autoantibody-secreting hybridomas obtained favors the presence of a high percentage of activated B lymphocytes with these same specificities in vivo. The presence of large numbers of spontaneous immunoglobulin-secreting mononuclear cells in the blood of SLE patients with active disease supports this conclusion (8, 9) .
Recently, Solomon et al. (33) produced murine monoclonal anti-idiotypic antibody directed against anti-DNA from one patient with SLE and found that one such monoclonal anti-idiotypic antibody also reacted with anti-DNA containing sera from eight of nine patients with SLE. In murine lupus models as well, anti-DNA immunoglobulins have been shown to share common idiotypes (34, 35) . Additionally, there is accumulating evidence for underlying B lymphocyte defects in lupus mice (36) . SLE patients may also share common idiotypes on their other autoantibodies. We theorize that semiautonomous B lymphocytes, which are relatively unresponsive to normal immunoregulatory signals, are responsible for autoantibody synthesis. These cells may be members of a clone descended from a cell affected by some event during B lymphocyte ontogeny that rendered that cell and its subsequent progeny semiautonomous. We plan to utilize these monoclonal autoantibodies to produce heterologous anti-idiotypic antibody. This could then be used to search for common idiotypes in the sera of SLE patients and isolate B lymphocytes bearing this idiotype. Such a finding would support this theory, have therapeutic implications, allow further study of autoantibody-producing cells, and possibly aid in early identification of potential SLE patients.
